Re: GLP-1 receptor agonist 비만과 당뇨치료를 넘어 2024 리뷰!!

[문형철]

위고비

인류에게 축복인 약으로 자리를 잡을까?

아니면 몇년내에 퇴출약물의 리스트레 오를까?  

Open AccessReview

GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes

by 

Sydney S. Wilbon

 and

Mikhail G. Kolonin

 *

The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center, Houston, TX 77030, USA

*

Author to whom correspondence should be addressed.

Cells 2024, 13(1), 65; https://doi.org/10.3390/cells13010065

Submission received: 22 November 2023 / Revised: 22 December 2023 / Accepted: 24 December 2023 / Published: 28 December 2023

Downloadkeyboard_arrow_down 

Browse Figure

Review Reports Versions Notes

Abstract

Glucagon-like peptide-1 receptor agonists (GLP1RA) have been transformative for patients and clinicians in treating type-2 diabetes and obesity. Drugs of this class, the bioavailability of which is continuously improving, enable weight loss and control blood glucose with minimal unwanted side effects. Since adopting GLP1RA for treating metabolic diseases, animal and clinical studies have revealed their beneficial effects on several other pathologies, including cardiovascular diseases, neurodegeneration, kidney disease, and cancer. A notable commonality between these diseases is their association with older age. Clinical trials and preclinical data suggest that GLP1RA may improve outcomes in these aging-related diseases. Some of the benefits of GLP1RA may be indirect due to their effects on obesity and glucose metabolism. However, there is building evidence that GLP1RA may also act directly on multiple organs implicated in aging-related pathology. This review aims to compile the studies reporting the effects of GLP1RA on aging-related diseases and discuss potential underlying mechanisms.

초록

글루카곤 유사 펩티드-1 수용체 작용제(GLP1RA)는 

제2형 당뇨병 및 비만 치료에서 환자 및 의료진에게 혁신적인 변화를 가져왔습니다. 

이 약물군은 

생체 이용률이 지속적으로 개선되고 있으며, 

최소한의 부작용으로 체중 감량과 혈당 조절을 가능하게 합니다. 

GLP1RA를 대사 질환 치료에 도입한 이후, 동

물 및 임상 연구에서 심혈관 질환, 신경퇴행성 질환, 신장 질환, 암 등

 다양한 질환에 대한 유익한 효과가 밝혀졌습니다. 

이러한 질환의 공통점 중 하나는 

노화와 연관되어 있다는 점입니다. 

임상 시험과 전임상 데이터는 

GLP1RA가 노화 관련 질환의 치료 결과를 개선할 수 있음을 시사합니다. 

GLP1RA의 일부 혜택은 

비만과 혈당 대사 조절을 통해 간접적으로 발생할 수 있습니다. 

그러나 

GLP1RA가 노화 관련 병리학에 관여하는 

다중 기관에 직접 작용할 수 있다는 증거가 점차 쌓이고 있습니다. 

이 리뷰는 

GLP1RA가 노화 관련 질환에 미치는 영향을 보고한 연구를 종합하고

 잠재적인 기전을 논의하는 것을 목표로 합니다.

Keywords: 

GLP-1 receptor agonist; aging; cancer; diabetes; incretin; obesity; neurodegenerative disease; cardiovascular disease

1. Introduction

Diabetes affects over 11% of the U.S. population and is currently the seventh leading cause of death. Aging and obesity are the main risk factors for type 2 diabetes (T2D) development, with about 40% of the diabetic population in the U.S. being over the age of 65 [1]. The leading causes of death in these patients with T2D are cardiovascular diseases and cancer due to their pathogenesis being aggravated by metabolic syndrome [2]. The recently approved glucagon-like peptide-1 receptor agonists (GLP1RA) have been groundbreaking in their ability to treat diabetes and obesity with a comparatively benign side effect profile. Despite the widespread adoption of these drugs, the extent of their therapeutic value has not fully been elucidated. These drugs were formulated to function like the endogenous glucagon-like peptide 1 (GLP1), an incretin hormone produced by L cells in the intestine. Postprandially, the levels of GLP1 increase dramatically to stimulate insulin biosynthesis and release, suppress glucagon release, delay gastric emptying, improve glucose metabolism, and increase satiety [3]. Driven by the discovery of the metabolic effects of GLP1 and its fragment exendin-4 (exenatide), pharmaceutical companies have developed improved GLP1 analogs for metronomic administration and sustained release. Several of these including liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and semaglutide (Ozempic, Rybelsus, and Wegovy) have been FDA-approved [4,5].

While GLP1RA had been initially indicated for T2D, liraglutide, and semaglutide have been subsequently approved for the management of obesity. Recently, semaglutide has also been approved to reduce the risk of cardiovascular events in patients with T2D and confirmed cardiovascular disease [6]. In addition, these agents have been noticed to reduce renal dysfunction [7] and liver steatosis [8].

The GLP1R is expressed and can be activated in various cells of the pancreas, digestive tract, heart muscle, skeletal muscle, liver, central nervous system, and immune system [9,10,11]. Given the multiple sites of GLP1R expression‎, many of its effects across the many tissues expressing it are yet to be fully understood. For example, clinical trials have shown that GLP1RA treatment to be protective against skeletal muscle wasting (Table 1). The risk of sarcopenia, T2D, cardiovascular disease, neurodegenerative disease, cancer, and renal disease is positively correlated with biological aging. The purpose of this review is to compile information on the systemic effects of GLP1RAs that could mediate their anti-aging effects via their activities in multiple organs (Figure 1). The synthesis of data on GLP1RA’s effects on pathways underlying the aging of vital organs provides new insights into how these therapeutics mitigate aging-associated diseases.

1. 서론

당뇨병은 미국 인구의 11% 이상에게 영향을 미치며 현재 사망 원인 중 7위를 차지하고 있습니다. 노화와 비만은 제2형 당뇨병(T2D) 발병의 주요 위험 요인으로, 미국 당뇨병 환자의 약 40%가 65세 이상입니다 [1]. T2D 환자의 주요 사망 원인은 대사증후군으로 인해 병리가 악화되는 심혈관 질환과 암입니다 [2].

최근 승인된

글루카곤 유사 펩티드-1 수용체 작용제(GLP1RA)는

비교적 경미한 부작용 프로파일로 당뇨병과 비만을 치료하는 데

혁신적인 효과를 보여주었습니다.

그러나 이러한 약물의 치료적 가치는 아직 완전히 규명되지 않았습니다.

이 약물은

장의 L 세포에서 생성되는 내인성 글루카곤 유사 펩티드 1(GLP1)과 유사하게 작용하도록

설계되었습니다.

식사 후 GLP1 수치는

급격히 증가하여 인슐린 생합성과 분비를 자극하고,

글루카곤 분비를 억제하며,

위 배출을 지연시키고,

포도당 대사 개선 및 포만감을 증가시킵니다 [3].

GLP1의 대사 효과와 그 단편인 엑센딘-4(엑세나티드)의 발견을 바탕으로 제약사들은

메트로노믹 투여 및 지속 방출을 위한

개선된 GLP1 유사체를 개발했습니다.

이 중

리라글루타이드(Victoza, Saxenda), 두라글루타이드(Trulicity),

세마글루타이드(Ozempic, Rybelsus, Wegovy) 등은

FDA 승인을 받았습니다[4,5].

GLP1RA는

초기에는 제2형 당뇨병(T2D) 치료에 사용되었으나,

리라글루티드와 세마글루티드는 이후 비만 관리에 승인되었습니다.

최근 세마글루티드는

T2D 및 확인된 심혈관 질환을 가진 환자의 심혈관 사건 위험 감소에도 승인되었습니다 [6].

또한 이 약물들은

신장 기능 장애 [7] 및 간 지방증 [8]을 감소시키는 것으로 관찰되었습니다.

GLP1R은

췌장, 소화관, 심장 근육, 골격근, 간, 중추 신경계, 면역계 등

다양한 세포에서 발현되고 활성화될 수 있습니다 [9,10,11].

GLP1R의 다중 발현 부위 고려 시,

이를 발현하는 다양한 조직에서의 효과는 아직 완전히 이해되지 않았습니다.

예를 들어, 임상 시험에서

GLP1RA 치료가 골격근 위축(표 1)에 대한 보호 효과를 보였습니다.

사르코페니아, 제2형 당뇨병(T2D), 심혈관 질환, 신경퇴행성 질환, 암, 신장 질환의 위험은

생물학적 노화와 양의 상관관계를 보입니다.

이 리뷰의 목적은 GLP1RAs가

다중 장기에서의 활동 통해 항노화 효과를 매개할 수 있는

체계적 효과를 정리하는 것입니다(그림 1).

GLP1RA가

주요 장기 노화 메커니즘에 미치는 영향에 대한 데이터의 통합은

이러한 치료제가 노화 관련 질환을 완화하는 메커니즘을 이해하는 데 새로운 통찰을 제공합니다.

Figure 1. The dichotomous effects of GLP1 receptor agonists (GLP1RA). Effects are labeled with blue font, with resulting physiological changes marked in bold. GLP1R is expressed in some but not all cell populations of organs shown. Direct signaling reported to have positive effects is indicated by blue connections. Effects unclear from literature or remaining to be tested/confirmed are marked with “?”. Indirect effects downstream of GLP1RA signaling are shown as black connections. GLP1RA have also been shown to decrease inflammation in multiple organs, which also likely contributes to their indirect beneficial effects.

Table 1. Summary of clinical trials showing the effects of GLP1RA in Sarcopenia.

2. GLP1RA Effects on Diabetes

The GLP1RA have been proven across multiple clinical trials to improve glucose control in patients with diabetes. In clinical studies, liraglutide has been shown to increase pancreatic β cell function, as shown by improved glucose tolerance and a corresponding decrease in HbA1C levels. GLP1RA have been found to increase glucose-stimulated C-peptide secretion, a surrogate for insulin secretion. Notably, GLP1RA-treated patients consistently have a significant decrease in their BMI [18]. Cessation of the drug most often causes a reversal of the beneficial effects [18]. However, there is evidence that these drugs may have long-term effects. In a study of patients taking exenatide for three years, patients had improved glucose-stimulated C-peptide secretion four weeks after drug cessation. Although this post-withdrawal effect did not translate to improved glycemic control, it does show that some beneficial alterations in β cell function are preserved with more long-term treatment [19].

There are several possible reasons for the improvement in glucose metabolism with the use of GLP1RA, but their effects on pancreatic β cells are of great significance. When tested in vivo in the genetic mouse model of obesity, exenatide decreased β cell endoplasmic reticulum (ER) stress signaling in pancreatic islets. Ex vivo, exenatide increased insulin production and protected isolated β cells from chemically induced apoptosis in a PKA-dependent manner [20]. In another study, infusion of GLP1 rescued rats from aging-related declines in insulin secretion and glucose tolerance. GLP1 also caused increased pancreatic mRNA expression‎ of glucokinase and glut2 [21]. GLP1RA have also been shown to improve hyperglycemia by increasing β cell mass. Exenatide and GLP1 both were able to increase pancreatic expression‎ of IDX-1, a transcription factor mediating β cell expansion [22]. These studies highlight the ability of GLP1RA to act as disease-modifying drugs in T2D. Long-term effects of incretin mimetics in other organs, including the immune system, adipose tissue (AT), liver, and skeletal muscle, have been proposed to contribute to their sustained anti-diabetic effects [23] (Figure 1).

3. GLP1RA Effects on Obesity

The preval‎ence of obesity in the U.S. has increased from 30.5% in 2000 to 41.9% in 2020 [24]. Although obesity rates are relatively stable across age groups, the metabolic derangements caused by obesity are cumulative over the lifespan. These abnormalities can progress to metabolic syndrome, characterized by hyperglycemia, hypertension, and dyslipidemia. There is increasing evidence that obesity and aging dysregulate many overlapping signaling pathways, including inflammation and oxidative stress, and that obesity accelerates the onset of aging-related diseases. In support of this, obese patients have decreased lifespans and poorer clinical outcomes compared to their lean counterparts. Obesity is a condition of AT overgrowth most often caused by an imbalance between caloric intake and expenditure [25]. AT is a heterogeneous metabolic and endocrine organ that is key in regulating energy homeostasis. It is prominent subcutaneously and around visceral organs but also exists in other metabolically distinct depots in the body. White adipose tissue (WAT) predominantly stores lipids for rapid mobilization, and brown adipose tissue (BAT) is responsible for non-shivering heat production [25]. Given the connection between obesity and aging, mechanisms by which GLP1RA affect AT signaling may provide new clues on their systemic physiological effects.

Semaglutide and liraglutide are the two GLP1RAs that have been FDA-approved to treat obesity. In a double-blinded, randomized control trial of type 2 diabetic patients, semaglutide treatment caused, on average, an extra 2.7 kg of body weight loss compared to patients on standard-of-care treatment [26]. Several other clinical trials have shown the ability of semaglutide to cause significant bodyweight loss [27,28]. Although not as effective as semaglutide, liraglutide also causes significant weight loss compared to placebo-treated patients [28,29]. There is also a novel non-peptide GLP1RA, orforglipron, that causes significant weight loss in overweight and obese patients, but it is not yet FDA-approved [30]. GLP1R agonism has confirmed benefits in obesity, but the mechanisms behind these changes are still being studied.

AT mass control has been attributed, in part, to the effects of GLP1RA on the sympathetic nervous system (SNS) and appetite suppression [31]. The “inducible/recruitable” brown-like (beige) adipocytes arise in subcutaneous AT (SAT) in response to catecholamine activation of adrenergic receptors. Receptor activation dramatically increases the metabolism of both glucose and fatty acids, thereby partially counteracting the metabolic consequences of obesity [32,33]. Thermogenic AT activation by prolonged GLP1 analog treatment has been reported for both mice and humans [34,35]. We recently reported that liraglutide treatment transiently induced interleukin-6 (IL6) in circulation and AT beiging in prediabetic patients and that this effect was recapitulated in the mouse model of obesity. The GLP1R-IL6 receptor signaling axis was shown to activate adipocyte lipolysis and thermogenesis [36]. Recombinant GLP1, beinaglutide, was also found to induce WAT beiging linked with its anti-obesity effects [37]. IL6 receptor knockout mice lack the increase in adipocyte beiging, energy expenditure, and glucose clearance in response to liraglutide treatment, demonstrating the GLP1RA signal through IL6 to increase adipocyte metabolism [36]. In addition, GLP1 and liraglutide have both been shown to increase the number of proliferating pre-adipocytes and induce differentiation of adipocytes [38]. Adipocyte hyperplasia, instead of hypertrophy, in response to lipid excess, is protective against insulin resistance and ectopic fat deposition in other organs [38]. Therefore, GLP1RA may protect from obesity and its consequences at least in part by increasing adipocyte hyperplasia and inducing AT beiging to increase energy expenditure. Notably, the knockout of the IL6 receptor in adipose cells did not negate the anti-obesity effect of liraglutide, indicating that GLP1RA signaling in the CNS may be more important for weight loss [36]. Future studies will be needed to establish if weight loss caused by GLP1RA is solely due to reduced food intake or whether GLP1RA signaling in AT contributes to their anti-obesity effect (Figure 1).

4. GLP1RA Effects on Cardiovascular Disease

Cardiovascular disease (CVD) is a significant cause of morbidity and mortality worldwide and is the number one cause of death in the U.S. [39]. CVD has the highest preval‎ence in the aged population, with incidences increasing from ~5% in those 18–44 to almost 35% in the 65+ population. Despite there being effective interventions to prevent and treat CVD, the rate in the 65+ population only saw a 4% decrease in incidence between 2008 and 2018 [40]. Molecular mechanisms of aging underlying the incidence and progression of CVD have not been sufficiently explored as a potential treatment target.

GLP1RA have shown efficacy and promise in the context of CVD. The results from various clinical studies show the multifactorial effects GLP1RA have on the cardiovascular system (Table 2). A meta-analysis of trials testing multiple GLP1RA in diabetic patients revealed that major adverse cardiovascular events, including stroke, myocardial infarction, and cardiovascular death, decreased by 12% in treated patients irrespective of the drug used or the population studied. Patients taking GLP1RA also experienced a 9% reduction in hospitalizations due to heart failure [41]. Interestingly, a rare missense mutation in the GLP1R appears to confer a reduced risk for coronary heart disease development [42]. In a study of diabetic patients, exenatide was found to transiently suppress the expression‎ of inflammatory markers TNFα and IL-1β. In this study, treatment for 12 weeks reduced the circulating levels of proinflammatory mediators like MCP-1, serum amyloid A, and IL6. Notably, these long-term effects of chronically high and pathogenic IL6 are distinct from the short-term beneficial effects of GLP1RA on IL6 secretion [36]. The long-term effects of GLP1RA were also independent of weight loss [43]. Because much of the clinical trial data is limited to patients with diabetes, obesity, or both, it is possible that the disease-modifying effects of GLP1RA are due to the mitigation of metabolic abnormalities associated with these conditions. However, results from preclinical studies [44,45,46,47] suggest that at least some of the benefits are due to a direct effect of GLP1RA in the cardiovascular system (Figure 1). Future studies in aging lean and non-diabetic patients may help to determine how much GLP1RA directly benefits cardiovascular diseases and contribute to clinical outcomes.

Table 2. Summary of clinical trials showing the effects of GLP1RA in cardiovascular diseases.

In support of the clinical data, the mechanisms behind the beneficial effects of GLP1RA on CVD have begun to surface. Liraglutide has been shown to ameliorate inflammatory signaling in the atria of infarcted mice, induce transcription of structural proteins, and protect cells from ER stress by upregulating heat shock proteins. In this model, knockout of the GLP1R in endothelial cells extinguished the beneficial effects of liraglutide, as shown by diminished ejection fraction and larger infarct size compared to mice with intact GLP1R expression‎ [44]. Consistent with these results, exenatide increased contractility of atria isolated from humans. Inhibitors of calcium release and the cAMP/PKA pathway blunted the positive ionotropic effect of exenatide, implying that the GLP1RA signal through this pathway improves atrial function [45]. In addition to endothelial cells, vascular smooth muscle cells (VSMC) play a pivotal role in the health of the cardiovascular system. In accordance with what has been shown in endothelial cells, exenatide was found to reduce angiotensin II-mediated VSMC senescence by reducing oxidative stress [47]. Exenatide has also been shown to decrease inflammatory signaling and the conversion of macrophages challenged with ox-LDL into foam cells, a culprit in atherosclerotic disease [46]. These preclinical studies highlight some of the direct effects of GLP1RA on CVD pathogenesis and progression.

5. GLP1RA Effects on Neurodegenerative Diseases

Neurodegenerative diseases are a group of disorders of the nervous system. Alzheimer’s disease (AD), the most common of them, is a progressive dementia characterized by the accumulation of misfolded beta-amyloid plaques and phosphorylated tau tangles in the brain. Age is the most significant risk factor for AD, with rates as high as 33% in the population older than 85; AD is the fifth leading cause of death in those 65 or older [56]. Large cohort autopsy studies have demonstrated that the presence of protein aggregates in the aging brain is independent of clinical features of neurodegenerative disease, indicating that aberrant protein metabolism is a hallmark of aging in general [57]. While therapies aimed at misfolded proteins may have some benefit, new safe and effective approaches to suppress neurodegeneration are awaited.

In a recent analysis of three double-blinded, placebo-controlled clinical trials of GLP1RA in diabetic patients, investigators discovered that patients in the treatment arm had a decrease in dementia incidence compared to placebo [58]. Moreover, GLP1RA-treated patients also had a reduced rate of dementia when compared to patients taking other anti-diabetic medications in a nationwide cohort of diabetic patients. Interestingly, these patients also had decreased mortality compared to patients who died without dementia, demonstrating a possible lifespan benefit with GLP1RA treatment compared to other anti-diabetic drugs [58]. In another randomized, placebo-controlled clinical trial in obese, prediabetic, and early diabetic patients testing the effect of liraglutide against a dietary and exercise intervention, patients who received liraglutide showed improvement in composite memory scores and exposure to GLP1RA was positively correlated with changes in memory scores. These benefits were seen despite comparable weight loss and glycemic control, indicating that the effect on cognitive function is independent of the effect on weight and hyperglycemia [59]. In the REWIND clinical trial, a double-blinded randomized control trial of diabetic patients with cardiovascular risks, dulaglutide reduced the probability of cognitive decline [60]. These trials highlight the ability of GLP1RA to suppress neurodegeneration associated with aging (Table 3).

Table 3. Summary of clinical trials showing the effects of GLP1RA in neurodegenerative diseases.

Consistent with these encouraging clinical trial results, the possible mechanisms of GLP1RA action in the brain have been elucidated in preclinical studies. It has been shown that liraglutide improves performance in the novel object recognition test and water maze task in APP/PS1 mice, a mouse model of AD. Importantly, these mice also showed decreased plaque burden in the cortex and reduced microglial activation, indicative of decreased inflammation and improved proteostasis. Liraglutide treatment in this model also restored the proliferation of neurons in the dentate gyrus and increased the number of synapses compared to control mice [64]. Liraglutide also improved memory retention in the SAMP8 mouse, a mouse model of accelerated aging and sporadic AD. This model demonstrated a liraglutide-dependent increase in the number of CA1 pyramidal neurons in the hippocampus region implicated in human memory loss [65]. In an in vitro model of beta-amyloid toxicity in neurons, treatment with semaglutide reversed the negative effects of beta-amyloid on cell viability by increasing the expression‎ of an anti-apoptotic effector, Bcl-2, and decreasing the expression‎ of pro-apoptotic effector, Bax. Semaglutide-treated neurons also displayed autophagy restoration that was compromised by beta-amyloid treatment [66]. Likely, the ability of GLP1RA to mitigate obesity and hyperglycemia partly accounts for their effects on the CNS. However, the potential importance of direct effects of GLP1RA on the cells of the brain, possibly mediated by their anti-inflammatory effects, will need to be further investigated.

6. GLP1RA Effects on Kidney Disease

About 14% of the adult U.S. population has chronic kidney disease (CKD), the progressive decline in kidney function that can be due to several etiologies [67]. The health of the kidneys can be determined using the estimated glomerular filtration rate (eGFR). eGFR in healthy individuals aged 20–40 is about 107 mL/min/1.73 m2 and undergoes a natural decline of 0.7 mL/min/1.73 m2 per year. Because of this natural aging-related decline, most healthy adults will have a low eGFR of <60 mL/min/1.73 m2 by 75 years old, which merits the diagnosis of CKD. Although these otherwise healthy patients do not experience proteinuria or any major increase in their relative risk of all-cause mortality, the high preval‎ence of chronic diseases like diabetes, obesity, and hypertension in the aged population exacerbates this natural aging-related decline in eGFR [68]. With the overwhelming evidence of the beneficial effects of GLP1RA on diabetes and obesity, it is important to better understand their ability to improve renal outcomes in the aged population.

In a nationwide cohort study comparing diabetic patients taking long-acting insulin vs. GLP1RA, the use of GLP1RA was associated with a lower risk of CKD progression, dialysis initiation, and renal death [69]. This finding is in accordance with an earlier trial comparing insulin glargine and dulaglutide in diabetic patients with moderate to severe CKD. These authors found that dulaglutide-treated patients had a higher eGFR than those on insulin [70]. Dulaglutide has also been previously shown to decrease the occurrence of new-onset macroalbuminuria, and treated patients had lower urinary albumin to creatinine ratio on follow-up [71]. Interestingly, adjusting for the decrease in HbA1C in the treatment group attenuated the renal effects of dulaglutide by about 26%, suggesting that the efficacy of GLP1RA is independent of their ability to alter this major CKD risk factor [71]. A separate randomized, placebo-controlled clinical trial testing the not-yet-approved GLP1RA efpeglenatide demonstrated a significant reduction in urinary albumin/creatinine ratio and increased eGFR. These beneficial effects were significantly independent of SGLT2 inhibitors and metformin use, again consistent with the possibility that the GLP1RA mechanism of action is independent of the effects of the standard-of-care drugs [55]. In addition to previously reported clinical data, the recently undertaken FLOW clinical study, a double-blinded, randomized control trial eval‎uating the ability of semaglutide to reduce kidney outcomes in patients with T2D and eGFR between 50 and 75 mL/min/1.73 m2 was stopped early by an independent data monitoring committee due to meeting prespecified criteria for efficacy. The trial’s primary endpoints included time to first kidney failure (persistent eGFR < 15 mL/min/1.73 m2 or initiation of chronic kidney replacement therapy), persistent ≥ 50% reduction in eGFR, or death from kidney or CV causes [72,73]. This and previous clinical trials give evidence supporting the role of GLP1RA in treating CKD (Table 4). However, more research is needed to understand how these drugs function in the kidney.

Table 4. Summary of clinical trials showing the effects of GLP1RA in renal disease.

The mechanism of action of GLP1RA on the renal system and, subsequently, the occurrence and progression of CKD appears to be multifactorial. One mechanism involves the ability of GLP1RA to reduce tubular damage and inflammation in the kidney. It has been reported that overexpression‎ of GLP1 in the db/db mouse model of obesity reduces histological markers of tubulointerstitial damage and reduces renal mRNA expression‎ of pro-inflammatory markers Tnfa and Ccl5. These expression‎ changes were accompanied by decreased renal infiltration of CD3+ T cells and F4/80+ macrophages. GLP1-overexpressing mice also had a significant survival advantage [76]. Consistent with that, it has been reported that global GLP1R knockout causes spontaneous kidney injury characterized by albuminuria and glomerulosclerosis that is exacerbated in streptozotocin-treated mice, a model of type-1 diabetes. This study also demonstrated the ability of liraglutide to improve podocyte architecture, albuminuria, and glomerulosclerosis. These histological markers corresponded with decreased expression‎ of the inflammatory mediator NF-κB, and monocyte chemoattractant MCP-1. Despite the lack of detectable change in glycemia, similar results were seen in the liraglutide-treated nephrectomized rats, a non-diabetic kidney disease model. This study highlights the importance of GLP1 activity in baseline kidney function and establishes the utility of GLP1RA even outside of diabetic kidney disease [77]. In addition to the beneficial roles of GLP1R activation on fibrosis and proteinuria, this pathway has also been shown to alter renal hemodynamics. GLP1 infusion in rats was shown to increase renal blood flow, eGFR, and urine output in a PKA-dependent manner. In this model, the effect was mediated by the phosphorylation of a Na+/H+ transporter NHE3 at PKA consensus sites, causing its inhibition [78]. Others have confirmed these findings and further concluded that exenatide-induced diuresis via PKA-dependent phosphorylation of NHE3 causes a decrease in blood pressure in the db/db mouse model [79]. Combined, these preclinical studies point to the mechanisms behind the beneficial effects of GLP1RA seen in clinical trials on kidney disease.

7. GLP1RA Effects on Cancer

In the U.S., cancer is the seventh leading cause of death, and the incidence of most cancers increases with age, with the population older than 55 accounting for 78% of all new diagnoses [80]. Interpreting the effects of GLP1RA on cancer initiation and progression is complicated due to the diversity of malignant diseases. Differences in the expression‎ of the GLP1R in different tumors or differential expression‎ between healthy and diseased tissue could partially explain this differential effect on different cancers. A study on the expression‎ of the GLP1R in cancerous and normal tissues showed that the GLP1R had the highest expression‎ in endocrine tumors. It also showed expression‎ in embryonic tumors, tumors of the nervous system, and some carcinomas [81]. In normal tissues resected at the same time as the tumor, expression‎ was found in the central nervous system, pancreas, small and large intestines, breast, lung, and kidney tissues [81]. The effects of GLP1A seem to depend on the specific tumor type being studied. For this reason, the benefit of GLP1RA on cancer outcomes and their beneficial effects on other diseases of aging must be weighed against the potential increased risk of some cancers.

Semaglutide has a boxed warning from the FDA about its potential for causing thyroid C-cell tumors, specifically medullary thyroid carcinoma [82]. Subsequent clinical data have confirmed this finding. A study of the FDA adverse event reporting system identified an increased risk of thyroid cancer in GLP1RA-treated patients when compared to patients on metformin; however, the increased rate of thyroid cancer was not significant in the liraglutide-treated groups, showing that the cancer association may be drug-dependent and not a feature of the entire class of drugs [83]. A similar study of this database found that GLP1RA usage was associated with increased incidence of not only thyroid cancers but also pancreatic and neuroendocrine neoplasms [84]. Semaglutide does have a warning label about the risk of pancreatitis, although it does not mention the risk of pancreatic cancer [82]. Pancreatitis is a risk factor for pancreatic cancer, and an increased risk of pancreatic cancer with GLP1RA usage has been shown in some studies [85].

On the other hand, a meta-analysis of randomized clinical trials and a systematic review of observational studies reported no increased risk of pancreatitis or pancreatic cancer in patients treated with GLP1RA [86,87]. Moreover, for many malignancies, there is evidence of an association between GLP1R activation and reduced cancer incidence. Increased fasting GLP1 plasma concentrations are associated with decreased first incidence of cancer [88]. Although GLP1RA often cause super-physiological levels of GLP1R activation, this study provides evidence that GLP1R signaling may decrease cancer risk. In a review of randomized control trial data, liraglutide was shown to decrease the risk of prostate cancer. However, no significant positive or negative relationship was found with any other cancer type [89]. A separate study of the FDA adverse event reporting system found that GLP1RA usage was linked with a significant decrease in not only prostate cancer but also colon and lung cancer [83]. The differences in outcomes from these studies could be explained by differences in length of follow-up, type of GLP1RA used, and characteristics of the study populations. Considering these mixed data, it is crucial to better understand the role of GLP1R agonism in cancer as these drugs become more widely adopted.

In support of the possible benefits of GLP1RA for patients with cancer, it has been reported that exenatide inhibits the proliferation of prostate cancer cells. This effect is attenuated by GLP1R knockdown or treatment with a GLP1R antagonist. In the same study, researchers showed in vivo that exenatide treatment caused a significant decrease in prostate tumor size with no effect on body weight or glucose levels [90]. Another study of exenatide in prostate cancer showed its ability to cause cell cycle arrest in vitro in an AMPK-dependent manner and to sensitize prostate cancer to ionizing radiation in vitro and in vivo [91]. The preclinical evidence on the benefits of GLP1R in other types of cancer is sparse and mixed. One group has reported that exenatide inhibits proliferation and induces apoptosis of the mouse CT26 colon cancer cell line and increases their susceptibility to topoisomerase inhibitor irinotecan. In vivo, exenatide treatment of orthotopic CT26 tumors showed no change in tumor weight; however, these tumors had increased TUNEL staining and decreased BrdU incorporation, indicating increased intra-tumoral apoptosis and decreased cell proliferation. Despite these positive findings for CT26 cells, GLP1R expression‎ was not observed in any other human or mouse colon cancer cell line tested [92]. A subsequent study found that exenatide only had a growth inhibitory effect on CT26 cells and did not affect cell death, migration, or adhesion in vitro or tumor growth in vivo for any other colon cancer cell line tested [93]. Nevertheless, liraglutide has been shown to decrease tumor size in orthotopic models of lung cancer and liver cancer, and it increased the sensitivity of both tumors to immune checkpoint blockade. After surgical resection of the primary tumor, orthotopic transplant of the same cancer cell line on the opposite side had decreased tumor growth, demonstrating a possible sustained anti-tumor effect of GLP1RA [94]. These studies suggest the possibility that the beneficial effects of GLP1RA in cancer are mediated by their effects on non-malignant cells in the tumor microenvironment.

It is important to note that, like the other diseases discussed in this review, metabolic syndrome is a risk factor for many types of cancer, namely, that of the liver, pancreas, colon, and breast [80]. Therefore, the anti-cancer effects of GLP1RA could be an indirect result of its glucose control and weight management (Figure 1). However, lung and prostate cancers, which have been found to be suppressed by GLP1RA in mouse models, are not strongly associated with diabetes [80]. This finding indicates that the anti-cancer effects of GLP1RA are, at least in these cases, mediated by direct effects independent of their effects on metabolism. The conflicting data on the role of GLP1RA in human cancers could be due to several factors, including the type of tumor, the design of the clinical trials, the specific GLP1RA used, or the population being studied. The increasing use of GLP1RA in populations with cancer and at risk for cancer development will help better define their potential benefits for individual cancer types.

8. GLP1RA Effects on Cellular Aging

Aging is unavoidable; however, there is an important distinction between chronological and biological age. Biological age can be altered by diet, physical activity, and various environmental factors. With the growing aging population, it is crucial to elucidate the mechanisms underlying healthy aging and develop treatments that augment these mechanisms. Biological aging is driven by multiple factors, including telomere shortening, epigenetic changes, stem cell exhaustion, mitochondrial dysfunction, genome instability, impaired protein metabolism, and abnormal nutrient sensing. All these cellular changes can induce apoptosis or cellular senescence, a state characterized by irreversible cell cycle arrest, a proinflammatory senescence-associated secretory phenotype (SASP), and expression‎ of senescence markers [95,96]. Accumulation of senescent cells is responsible for tissue changes leading to aging-related diseases [97,98]. Because cell senescence contributes to biological aging [99], approaches to suppress or reverse senescence would be integral in preventing and treating aging-associated diseases [100].

Evidence from preclinical studies has suggested that GLP1R activation can suppress some cellular changes that accompany aging. It has been shown that the shortening of telomeres and a decline in DNA repair mechanisms induce cell senescence and aging [100]. In fact, mutations in DNA repair genes are responsible for Werner Syndrome and Hutchinson–Gilford progeria syndrome, the diseases of accelerated aging [99]. It was recently reported in non-human primates that plasma GLP1 levels in adolescents were positively correlated with their adult telomere length, showing a possible association between GLP1R activity and telomere maintenance [101]. Base excision repair is the primary pathway of DNA damage repair in neurons. The GLP1RA exenatide ameliorates drug-induced ROS production in neurons by increasing expression‎ of the base excision repair protein, APE1, and activating this geno-protective pathway in vitro and in vivo [102]. Exenatide was also shown to decrease the number of senescent endothelial cells and improve their survival after a hydrogen peroxide challenge by modulating signaling through Sirt1, PPARγ, and PGC1α [103]. Moreover, exenatide can alleviate angiotensin II-mediated senescence in VSMC [47]. In this study, the decrease in cell senescence was accompanied by improved proliferative capacity and decreased oxidative stress. This body of evidence suggests that GLP1RA may be able to delay aging through a multi-pronged mechanism suppressing cell senescence and maintaining genomic integrity.

Caloric restriction is an intervention that has consistently been shown to extend lifespan across organisms. With caloric restriction, there are intracellular changes in energy-sensing pathways that integrate the metabolic state and alter signaling pathways. mTOR and AMPK signaling are the key nutrient-sensing pathways that mediate the beneficial effects of caloric restriction on longevity [99]. It has been shown that activation of AMPK increases the lifespan [104,105]. In a study of diabetic rats, the GLP1RA exenatide decreased cardiomyocyte apoptosis and improved cardiac function. This effect was associated with increased AMPK phosphorylation, activating its activity [106]. In addition, it has been reported that liraglutide ameliorates the lipotoxic, inflammatory effects of high-calorie diet feeding in vivo and palmitic acid treatment in vitro via inhibition of the mTORC1 signaling pathway [107]. In another study, in vitro treatment of endothelial cells with liraglutide caused mTORC2-dependent AKT phosphorylation and release of nitric oxide (NO). Importantly, this study provides evidence of a liraglutide-mediated increase in telomerase activity and its translocation to the nucleus [108]. Telomerase not only lengthens telomeres to prevent their attrition [109,110] but is also implicated in protection from genotoxic stress [111] and has genome-wide telomere-independent effects on gene expression‎ and cell metabolism [112]. There is accumulating evidence that inactivation of telomerase is a key contributor to cell aging, leading to senescence [113]. We have reported that telomerase inactivation in adipose progenitor cells causes cellular senescence and predisposes mice to AT dysfunction and T2D [114]. Conversely, telomerase gene therapy delays aging and increases longevity without increasing cancer incidence in mice [115]. It is tempting to speculate that the effect of GLP1RA on telomerase and nutrient sensing pathways may account for their beneficial role in diseases of aging. However, it is apparent that healthy aging can also be promoted by the positive effects of GLP1RA on multiple individual organs that collectively improve physiological homeostasis (Figure 1).

8. GLP1RA의 세포 노화への 영향

노화는 피할 수 없는 현상이지만, 연령과 생물학적 연령 사이에는 중요한 차이가 있습니다. 생물학적 연령은 식습관, 신체 활동, 다양한 환경 요인에 의해 변화될 수 있습니다. 고령화 인구가 증가함에 따라 건강한 노화의 메커니즘을 규명하고 이러한 메커니즘을 강화하는 치료법을 개발하는 것이 중요합니다. 생물학적 노화는 텔로미어 단축, 에피제네틱 변화, 줄기세포 고갈, 미토콘드리아 기능 장애, 유전체 불안정성, 단백질 대사 장애, 영양소 감지 이상 등 다양한 요인에 의해驱动됩니다. 이러한 세포 변화는 세포 사멸 또는 세포 노화 상태를 유발할 수 있으며, 이는 세포 주기 정지, 염증성 노화 관련 분비 형질(SASP), 노화 표지자 발현으로 특징지어집니다 [95,96]. 노화 관련 질환으로 이어지는 조직 변화는 노화 세포의 축적에 기인합니다 [97,98]. 세포 노화가 생물학적 노화에 기여하기 때문에 [99], 노화를 억제하거나 역전시키는 접근법은 노화 관련 질환의 예방 및 치료에 필수적일 것입니다 [100].

전임상 연구 결과는

GLP1R 활성화가

노화와 동반되는 일부 세포 변화를 억제할 수 있음을 시사합니다.

텔로미어 단축과 DNA 복구 메커니즘의 감소가

세포 노화와 노화를 유발한다는 것이 밝혀졌습니다 [100].

실제로 DNA 복구 유전자의 변이는

가속화된 노화 질환인 Werner 증후군과 Hutchinson–Gilford progeria 증후군의 원인으로 알려져 있습니다 [99].

최근 비인간 영장류에서

청소년기의 혈장 GLP1 수치가 성인기의 텔로미어 길이와 양의 상관관계를 보였으며,

이는 GLP1R 활성과 텔로미어 유지 사이의 가능성 있는 연관성을 시사합니다 [101].

기저 절제 복구는

신경세포에서 DNA 손상 복구의 주요 경로입니다.

GLP1 수용체 억제제인 엑세나티드는

신경세포에서 약물 유발성 활성산소종(ROS) 생성을 감소시키며,

기저 절제 복구 단백질 APE1의 발현을 증가시키고

이 유전적 보호 경로를 체외 및 체내에서 활성화합니다 [102].

엑세나티드는

Sirt1, PPARγ, PGC1α 신호전달 경로를 조절하여

수소 과산화물 자극 후 노화 내피 세포의 수를 감소시키고 생존율을 개선했습니다 [103].

또한 엑세나티드는

VSMC에서 안지오텐신 II에 의한 노화를 완화합니다 [47].

이 연구에서 세포 노화의 감소는

증식 능력의 개선과 산화 스트레스의 감소와 동반되었습니다.

이러한 증거들은

GLP1RA가 세포 노화를 억제하고 유전체 무결성을 유지하는

다중 기전을 통해 노화를 지연시킬 수 있음을 시사합니다.

칼로리 제한은

다양한 생물체에서 수명을 연장하는 것으로 일관되게 입증된 개입 방법입니다.

칼로리 제한 시 에너지 감지 경로에서 세포 내 변화가 발생하며,

이는 대사 상태를 통합하고 신호 전달 경로를 변경합니다.

mTOR 및 AMPK 신호 전달 경로는

칼로리 제한의 수명 연장 효과를 매개하는 주요 영양 감지 경로입니다 [99].

AMPK 활성화가 수명을 연장한다는 것이 입증되었습니다 [104,105].

당뇨병 쥐 모델에서 GLP1RA 억제제인 엑세나티드는

심근 세포 사멸을 감소시키고 심장 기능을 개선했습니다.

이 효과는 AMPK 인산화 증가와 그 활성 활성화와 연관되었습니다 [106].

또한, 리라글루티드는

고열량 식이 투여 시 체내에서 및 팔미트산 처리 시 체외에서 mTORC1 신호전달 경로의 억제를 통해

지질 독성 및 염증 효과를 완화한다는 보고가 있습니다 [107].

다른 연구에서, 체외에서 내피 세포에

리라글루타이드를 처리했을 때

mTORC2 의존적 AKT 인산화 및 질산산화물(NO) 방출이 발생했습니다.

중요하게도, 이 연구는 리라글루타이드에 의한 텔로머라제 활성 증가 및 핵으로의 이동을 입증했습니다 [108]. 텔로머레이스는 텔로머르의 단축을 방지하기 위해 텔로머르를 연장하는 역할을 합니다 [109,110]. 또한 유전독성 스트레스로부터의 보호 [111] 및 텔로머르 독립적인 유전체 전체 유전자 발현과 세포 대사 조절에 영향을 미칩니다 [112]. 텔로머레이스 비활성화가 세포 노화의 주요 요인으로 작용하여 노화 및 세포 사멸을 유발한다는 증거가 누적되고 있습니다 [113]. 우리는 지방 전구 세포에서 텔로머레이스 비활성화가 세포 노화를 유발하고 쥐에서 AT 기능 장애와 제2형 당뇨병(T2D)에 취약하게 만든다는 것을 보고했습니다 [114]. 반면, 텔로머레이스 유전자 치료는 쥐에서 암 발생률을 증가시키지 않으면서 노화를 지연시키고 수명을 연장합니다 [115]. GLP1RA가 텔로머라제와 영양 감지 경로에 미치는 영향이 노화 관련 질환에서의 유익한 역할을 설명할 수 있다는 추측이 가능합니다. 그러나 GLP1RA가 여러 개별 장기에서 긍정적인 영향을 미쳐 생리적 균형을 종합적으로 개선함으로써 건강한 노화를 촉진할 수 있다는 점은 명확합니다 (그림 1).

9. Conclusions

The widespread adoption of GLP1RA has been instrumental in controlling glucose metabolism and supporting adiposity management in diabetic and overweight patients. Clinical trials have revealed that GLP1RA signaling spans beyond the pancreas and brain, potentially explaining their beneficial effects in other organs (Table 1, Table 2, Table 3 and Table 4). GLP1RA appear to suppress aging-related diseases in the cardiovascular system, kidney, and other organs (Figure 1). Diabetes and obesity both predispose patients to cardiovascular diseases, neurodegenerative diseases, and many other diseases of aging. Therefore, some of the benefits from GLP1RA therapy are likely to be secondary to the improvement in whole-body glucose metabolism through effects on the pancreas and adipose tissue control through effects on the central nervous system. However, accumulating evidence from preclinical models indicates that GLP1RA directly signal in multiple organs by inducing cellular pathways that prevent pathogenesis and/or suppress disease progression. Going forward, it will be important to better understand the organ-specific and cell type-specific roles of GLP1RA and their possible effects, likely synergizing with the benefits of GLP1RA on metabolism and body composition.

With the widespread beneficial effects of GLP1RA on the body, many regard them as miracle drugs. As newer anti-diabetic therapies come to market, it will be important to eval‎uate their systemic effects in the context of the anti-aging benefits of GLP1RA discussed in this review. The newly developed dual agonists, which activate both GLP1R and glucose-dependent insulinotropic peptide (GIP) receptor (GIPR), appear more efficacious than GLP1RA alone in reducing HbA1C and body weight [116]. Dual agonists have been extensively reviewed elsewhere [117,118,119,120,121] and tirzepatide (Zepbound) was recently FDA-approved. Like the GLP1RA, dual agonists have shown efficacy in aging-related diseases besides diabetes and obesity including cardiovascular disease [119,120,122], neurodegenerative diseases [123,124,125], and kidney disease [126]. In the future, it will be important to determine if/how the addition of GIP agonism affects the anti-aging effects of GLP1RA. Ultimately, expanding the indications for GLP1RA, and possibly dual agonists, beyond diabetes and obesity could improve health and prolong healthy aging in a more general population.

9. 결론

GLP1RA의 광범위한 채택은

당뇨병 및 과체중 환자의 혈당 대사 조절과 체지방 관리에 중요한 역할을 해왔습니다.

임상 시험은

GLP1RA 신호전달이 췌장과 뇌를 넘어 다른 장기에서도 작용함을 보여주며,

이는 다른 장기에서의 유익한 효과를 설명할 수 있습니다(표 1, 표 2, 표 3 및 표 4).

GLP1RA는

심혈관 시스템, 신장 및 기타 장기에서 노화 관련 질환을 억제하는 것으로 나타났습니다(그림 1).

당뇨병과 비만은

모두 환자를 심혈관 질환, 신경퇴행성 질환 및 기타 노화 관련 질환에 노출시킵니다.

따라서

GLP1RA 치료의 일부 혜택은

췌장과 지방 조직 조절을 통해 중추 신경계에 미치는 영향으로 인한 전신 포도당 대사 개선에 따른

이차적 효과일 가능성이 있습니다.

그러나 전임상 모델에서 축적된 증거는 GLP1RA가 세포 내 경로를 유도하여 병리 발생을 방지하거나 질병 진행을 억제함으로써 다중 장기에서 직접 신호전달을 수행한다는 것을 나타냅니다. 향후 GLP1RA의 장기 특이적 및 세포 유형 특이적 역할과 대사 및 체성분 개선 효과와의 시너지 효과를 이해하는 것이 중요할 것입니다.

GLP1RA의 신체 전반에 걸친 유익한 효과로 인해

많은 사람들이 이를

기적의 약물로 간주합니다.

새로운 항당뇨병 치료제가 시장에 출시됨에 따라,

본 리뷰에서 논의된 GLP1RA의 항노화 효과를 고려하여

그 시스템적 효과를 평가하는 것이 중요할 것입니다.

최근 개발된 이중 작용제(GLP1R과 포도당 의존성 인슐린 분비 펩티드(GIP) 수용체(GIPR)를 모두 활성화하는 물질)는

GLP1RA 단독 투여보다 HbA1C와 체중 감소에 더 효과적입니다[116].

이중 작용제는 다른 곳에서 광범위하게 검토되었습니다[117,118,119,120,121]이며,

티르제파티드(Zepbound)는 최근 FDA 승인을 받았습니다.

GLP1RA와 마찬가지로 이중 작용제는 당뇨병과 비만 외에도 심혈관 질환[119,120,122], 신경퇴행성 질환[123,124,125], 신장 질환[126] 등 노화 관련 질환에서 효능을 보여주었습니다. 향후 GIP 작용제의 추가가 GLP1RA의 항노화 효과에 미치는 영향 여부 및 메커니즘을 규명하는 것이 중요할 것입니다. 궁극적으로 GLP1RA 및 잠재적으로 이중 작용제의 적응증을 당뇨병과 비만을 넘어 확장하는 것은 일반 인구에서 건강을 개선하고 건강한 노화를 연장하는 데 기여할 수 있습니다.

Author Contributions

Writing—original draft preparation, S.S.W. and M.G.K.; writing—review and editing, S.S.W. and M.G.K. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Bovay Foundation, the Levy-Longenbaugh Fund, and the National Institute of Health grants R21DK122234 and 1R01DK125922.

Acknowledgments

The figure was constructed using BioRender.com (accessed on 21 December 2023).

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Chia, C.W.; Egan, J.M.; Ferrucci, L. Age-Related Changes in Glucose Metabolism, Hyperglycemia, and Cardiovascular Risk. Circ. Res. 2018, 123, 886–904. [Google Scholar] [CrossRef] [PubMed]
2. Palta, P.; Huang, E.S.; Kalyani, R.R.; Golden, S.H.; Yeh, H.C. Hemoglobin A(1c) and Mortality in Older Adults With and Without Diabetes: Results From the National Health and Nutrition Examination Surveys (1988–2011). Diabetes Care 2017, 40, 453–460. [Google Scholar] [CrossRef] [PubMed]
3. Edwards, C.M.; Todd, J.F.; Mahmoudi, M.; Wang, Z.; Wang, R.M.; Ghatei, M.A.; Bloom, S.R. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: Studies with the antagonist exendin 9-39. Diabetes 1999, 48, 86–93. [Google Scholar] [CrossRef] [PubMed]
4. Muller, T.D.; Finan, B.; Bloom, S.R.; D’Alessio, D.; Drucker, D.J.; Flatt, P.R.; Fritsche, A.; Gribble, F.; Grill, H.J.; Habener, J.F.; et al. Glucagon-like peptide 1 (GLP-1). Mol. Metab. 2019, 30, 72–130. [Google Scholar] [CrossRef] [PubMed]
5. Knudsen, L.B.; Nielsen, P.F.; Huusfeldt, P.O.; Johansen, N.L.; Madsen, K.; Pedersen, F.Z.; Thogersen, H.; Wilken, M.; Agerso, H. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J. Med. Chem. 2000, 43, 1664–1669. [Google Scholar] [CrossRef] [PubMed]